Cargando…
Chinese Expert Consensus on Iodine(125) Seed Implantation for Recurrent Cervical Cancer in 2021
The treatment modality for recurrent cervical cancer (rCC) is limited, and the prognosis of these patients is poor. Seed implantation could be an important component of rCC management in the context of dose boost or salvage therapy after surgery or radiotherapy, which is characterized by a minimally...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630633/ https://www.ncbi.nlm.nih.gov/pubmed/34858802 http://dx.doi.org/10.3389/fonc.2021.700710 |
_version_ | 1784607401671917568 |
---|---|
author | Jiang, Ping Zou, Lijuan Wei, Lichun Cheng, Guanghui Sun, Baosheng Zhang, Fuquan Wang, Ruoyu Wang, Tiejun Qu, Ang Yuan, Xiangkun Qiu, Bin Wei, Shuhua Liu, Zi Zhang, Yunyan Wang, Junjie |
author_facet | Jiang, Ping Zou, Lijuan Wei, Lichun Cheng, Guanghui Sun, Baosheng Zhang, Fuquan Wang, Ruoyu Wang, Tiejun Qu, Ang Yuan, Xiangkun Qiu, Bin Wei, Shuhua Liu, Zi Zhang, Yunyan Wang, Junjie |
author_sort | Jiang, Ping |
collection | PubMed |
description | The treatment modality for recurrent cervical cancer (rCC) is limited, and the prognosis of these patients is poor. Seed implantation could be an important component of rCC management in the context of dose boost or salvage therapy after surgery or radiotherapy, which is characterized by a minimally invasive, high local dose, and rapidly does fall, sparing normal tissue. For patients with good performance status and lateral pelvic wall recurrence with an available puncture path, seed implantation was recommended, as well as for selected central pelvic recurrence and extra-pelvic recurrence. The combination of brachytherapy treatment planning system and CT guidance was needed, and three-dimensional printing templates could greatly improve the accuracy, efficiency, and quality of seed implantation to achieve a potential ablative effect and provide an efficient treatment for rCC. However, the recommendations of seed implantation were mainly based on retrospective articles and lack high-quality evidence, and multicenter prospective randomized studies are needed. In this consensus on iodine(125) seed implantation for rCC, indication selection, technical process and requirements, dosimetry criteria, radiation protection, combined systemic therapy, and outcomes of seed implantation for rCC are discussed. |
format | Online Article Text |
id | pubmed-8630633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86306332021-12-01 Chinese Expert Consensus on Iodine(125) Seed Implantation for Recurrent Cervical Cancer in 2021 Jiang, Ping Zou, Lijuan Wei, Lichun Cheng, Guanghui Sun, Baosheng Zhang, Fuquan Wang, Ruoyu Wang, Tiejun Qu, Ang Yuan, Xiangkun Qiu, Bin Wei, Shuhua Liu, Zi Zhang, Yunyan Wang, Junjie Front Oncol Oncology The treatment modality for recurrent cervical cancer (rCC) is limited, and the prognosis of these patients is poor. Seed implantation could be an important component of rCC management in the context of dose boost or salvage therapy after surgery or radiotherapy, which is characterized by a minimally invasive, high local dose, and rapidly does fall, sparing normal tissue. For patients with good performance status and lateral pelvic wall recurrence with an available puncture path, seed implantation was recommended, as well as for selected central pelvic recurrence and extra-pelvic recurrence. The combination of brachytherapy treatment planning system and CT guidance was needed, and three-dimensional printing templates could greatly improve the accuracy, efficiency, and quality of seed implantation to achieve a potential ablative effect and provide an efficient treatment for rCC. However, the recommendations of seed implantation were mainly based on retrospective articles and lack high-quality evidence, and multicenter prospective randomized studies are needed. In this consensus on iodine(125) seed implantation for rCC, indication selection, technical process and requirements, dosimetry criteria, radiation protection, combined systemic therapy, and outcomes of seed implantation for rCC are discussed. Frontiers Media S.A. 2021-11-09 /pmc/articles/PMC8630633/ /pubmed/34858802 http://dx.doi.org/10.3389/fonc.2021.700710 Text en Copyright © 2021 Jiang, Zou, Wei, Cheng, Sun, Zhang, Wang, Wang, Qu, Yuan, Qiu, Wei, Liu, Zhang and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Jiang, Ping Zou, Lijuan Wei, Lichun Cheng, Guanghui Sun, Baosheng Zhang, Fuquan Wang, Ruoyu Wang, Tiejun Qu, Ang Yuan, Xiangkun Qiu, Bin Wei, Shuhua Liu, Zi Zhang, Yunyan Wang, Junjie Chinese Expert Consensus on Iodine(125) Seed Implantation for Recurrent Cervical Cancer in 2021 |
title | Chinese Expert Consensus on Iodine(125) Seed Implantation for Recurrent Cervical Cancer in 2021 |
title_full | Chinese Expert Consensus on Iodine(125) Seed Implantation for Recurrent Cervical Cancer in 2021 |
title_fullStr | Chinese Expert Consensus on Iodine(125) Seed Implantation for Recurrent Cervical Cancer in 2021 |
title_full_unstemmed | Chinese Expert Consensus on Iodine(125) Seed Implantation for Recurrent Cervical Cancer in 2021 |
title_short | Chinese Expert Consensus on Iodine(125) Seed Implantation for Recurrent Cervical Cancer in 2021 |
title_sort | chinese expert consensus on iodine(125) seed implantation for recurrent cervical cancer in 2021 |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630633/ https://www.ncbi.nlm.nih.gov/pubmed/34858802 http://dx.doi.org/10.3389/fonc.2021.700710 |
work_keys_str_mv | AT jiangping chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 AT zoulijuan chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 AT weilichun chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 AT chengguanghui chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 AT sunbaosheng chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 AT zhangfuquan chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 AT wangruoyu chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 AT wangtiejun chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 AT quang chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 AT yuanxiangkun chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 AT qiubin chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 AT weishuhua chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 AT liuzi chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 AT zhangyunyan chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 AT wangjunjie chineseexpertconsensusoniodine125seedimplantationforrecurrentcervicalcancerin2021 |